Core Insights - Molecular Partners AG has entered into a partnership with Eckert & Ziegler to advance its Radio-DARPin therapeutics pipeline, focusing on imaging and therapeutic radio-isotopes, including Actinium-225 [1][2] Group 1: Partnership and Development - The agreement with Eckert & Ziegler will enhance the potential of Radio-DARPins for precise delivery of therapeutic alpha-emitting isotopes to tumors, including Actinium-225 and Lead-212 [2][3] - Eckert & Ziegler will provide a comprehensive range of services for the development of Radio-DARPins with Actinium-225 and Lutetium-177 payloads, utilizing its advanced laboratories [3] Group 2: Pipeline and Research - Molecular Partners is evaluating various radio-nuclides to tailor Radio-DARPin candidates to patient needs, aiming to match vector and isotope properties with target and disease biology [4] - The company plans to present pre-clinical data on the suitability of Radio-DARPins with multiple isotopes at the Global Radiopharmaceuticals Development Summit in March 2026 [4] Group 3: Technology and Innovation - Radio-DARPins are designed to deliver potent alpha-emitting isotopes to tumor lesions while minimizing toxicity to healthy tissues, addressing historical limitations of radioligand therapy [6][7] - The proprietary Radio-DARPin platform incorporates half-life extension technologies and surface engineering approaches to enhance therapeutic efficacy [6][7] Group 4: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for medical challenges that other treatment modalities cannot address [9] - The company has proprietary programs in various stages of pre-clinical and clinical development, alongside partnerships with leading pharmaceutical companies and academic centers [9]